Quantcast

IBD Rating Upgrades: Agios Pharmaceuticals Flashes Improved Relative Price Strength


Shutterstock photo

In a welcome move, Agios Pharmaceuticals ( AGIO ) saw its Relative Strength Rating rise from 63 to 77 on Tuesday.

[ibd-display-video id=2368044 width=50 float=left autostart=true] This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research reveals that the best stocks tend to have an RS Rating of over 80 in the early stages of their moves. See if Agios Pharmaceuticals can continue to show renewed price strength and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

While the stock is not near a proper buy zone right now, see if it manages to form and break out from a proper consolidation.

Earnings growth increased last quarter from 0% to 2%, but revenue fell from 63% to 26%.

Agios Pharmaceuticals earns the No. 168 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Emergent Biosolutions ( EBS ) and Hutchison China MediTech ( HCM ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: AGIO , CORT , EBS , HCM


More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing








Research Brokers before you trade

Want to trade FX?